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Introduction: Coagulation and fibrinolysis remain sparsely 
addressed with regards to acute respiratory distress syndrome 
(ARDS). We hypothesized that ARDS development might be 
associated with changes in plasma coagulation and fibrinolysis. 
Our aim was to investigate the relationships between ARDS 
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diagnosis and plasma concentrations of tissue factor (TF), tissue 
plasminogen activator (t-PA) and plasminogen activator 
inhibitor-1 (PAI-1) in mechanically ventilated patients at 
increased risk of developing ARDS.  
 
Materials and Methods: We performed an ethically approved 
prospective observational pilot study. Inclusion criteria: patients 
with PaO2/FiO2 < 300 mmHg admitted to the intensive care unit 
(ICU) for mechanical ventilation for 24 hours, or more, because 
of one or more disease conditions associated with increased risk 
of developing ARDS. Exclusion criteria: age below 18 years; 
cardiac disease. We sampled plasma prospectively and compared 
patients who developed ARDS with those who did not using 
descriptive statistics and chi-square analysis of baseline 
demographical and clinical data. We also analyzed plasma 
concentrations of TF, t-PA and PAI-1 at inclusion (T0) and on 
third (T3) and  seventh day (T7) of the ICU stay with non-
parametric statistics inclusive their sensitivity and specificity 
associated with the development of ARDS using receiver 
operating characteristic (ROC) curve analysis. Statistical 
significance: p < 0.05. 
 
Results: Of 24 patients at risk, six developed mild ARDS and 
four of each moderate or severe ARDS, respectively, 3 ± 2 
(Mean ± SD) days after inclusion. Median plasma concentrations 
of TF and PAI-1 were significantly higher at T7 in patients with 
ARDS, as compared to non-ARDS. Simultaneously, we found 
moderate correlations between plasma concentrations of TF and 
PAI-1, TF and PaO2/FiO2 and PEEP and TF. TF plasma 
concentration was associated with ARDS with 71% sensitivity 
and 100% specificity, a cut off level of 145 pg/ml and AUC 
0.78, p = 0.02. PAI-1 displayed 64% sensitivity and 100% 
specificity with a cut off concentration of 117.5 pg/ml and AUC 
0.77, p = 0.02. t-PA did not change significantly during the 
observation time. 
 
Conclusions: This pilot study showed that increased plasma 
concentrations of TF and PAI-1 might support ARDS diagnoses 
in mechanically ventilated patients after seven days in ICU. 
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Acute respiratory distress syndrome (ARDS) represents a severe 
respiratory failure characterized by hypoxia and non-hydrostatic 
pulmonary edema with bilateral opacities on frontal chest 
radiographs. Patients with ARDS require treatment in the 
intensive care unit (ICU) for respiratory support with continuous 
positive airway pressure (CPAP), or positive end-expiratory 
pressure (PEEP) of 5 cm H2O or higher in combination with 
mechanical ventilation [1-3]. Usually, ARDS occurs within one 
week of a triggering event [4, 5] and might be the result of a 
direct lung injury, as pneumonia, or an indirect lung injury, like 
septic shock [6-8].  
 
Incidence of ARDS displays large geographical differences 
[9,10]. A recent worldwide multicenter study showed that 10.4% 
of those admitted to participating ICUs and 23.4% of those 
requiring mechanical ventilation exhibited ARDS criteria. 
Hospital mortality varied between 34.9%, 40.3% and 46.1% for 
patients with respectively mild, moderate and severe ARDS [11]. 
This is consistent with mortality rates published by previous 
investigators [10,12,13]. Thus, despite a varying incidence, 
overall mortality from ARDS has not changed substantially 
during the last decade [14,15]. Consequently, identification of 
patients at risk should be prioritized with the aim to diagnose 
ARDS earlier, as recently proposed [16]. 
 
Several studies have focused on injury to the lung parenchyma, 
which then causes deteriorated gas exchange in ARDS [17-19]. 
In contrast, changes in homeostasis of coagulation and 
fibrinolysis have been sparsely investigated despite that their role 
in the evolution of this disease is beyond doubt. Investigators 
recently described a role in the interaction between lung 
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inflammation and the coagulation and the fibrinolytic systems 
for the commencement of ARDS [20,21].  
 
Inflammation modulates blood coagulation by activating C-
reactive protein, which stimulates monocytes and alveolar 
macrophages to generate tissue factor (TF) [5,22], and 
endothelial cells to produce plasminogen activator inhibitor-1 
(PAI-1) [23]. The combined effects can lead to disseminated 
intravascular coagulation (DIC) including formation of 
intravascular micro-thrombi and intra-alveolar fibrin deposits 
[5,23-25], subsequently increasing both dead-space ventilation 
and intrapulmonary shunting, both characteristic features of 
ARDS [24]. Consequently, we speculated that the circulatory 
level of TF, and the balance between inhibitors and activators of 
fibrinolysis, could be of help for the diagnosing of ARDS [22].  
 
In mechanically ventilated patients, whom we considered to be at 
increased risk of developing ARDS, we aimed to perform a pilot 
study to explore whether associations exist between diagnosis of 
ARDS and the plasma concentration of TF as the primary 
endpoint, and ARDS and plasma levels of PAI-1 and t-PA, 
respectively, as secondary endpoints. 
 
Material and Methods  
Patients Eligible for the Study  
 
Between November 2014 and February 2015, we transferred 33 
patients to the ICU of Pauls Stradins Clinical University Hospital 
(PSCU), Riga, Latvia, for mechanical ventilation because we 
considered them to be at increased risk of developing ARDS. 
After the Medical Ethics Committee of PSCU had approved the 
study protocol and the informed consent form (No. 18204-5 L), 
we screened the patients for suitability to participate in a 
prospective observational pilot study of the influence of plasma 
coagulation and fibrinolysis on the emergence of ARDS. We 
obtained informed consent from each one’s legal guardian prior 
to inclusion for those who were eligible for participation in the 
study. 
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According to their disease conditions, the patients were treated 
either with non-invasive pressure-controlled mechanical 
ventilation (NIV), or endotracheal intubation and mechanical 
ventilation with continuous positive airway pressure (CPAP) ≥ 5 
cm H2O, or positive end-expiratory pressure (PEEP) ≥ 5 cm H2O 
over 24 hours or more using Servo-I ventilators (Maquet 
Getinge, Group, Rastatt Germany). The patients received 
antibiotics, as required, based on the results of microbiological 
cultures and antibiotic resistance testing.  
 
Inclusion Criteria  
 
We included  patients with PaO2/FiO2 < 300 mmHg and with an 
increased risk of developing ARDS [24] because of one or more 
ARDS predisposing conditions causing either direct or indirect 
lung injury. The former included pneumonia or aspiration of 
gastric contents into the airways; the latter comprised of sepsis, 
acute pancreatitis, DIC, burns, drug overdose or trauma with 
circulatory shock and massive blood transfusions, as outlined by 
previous investigators [24]. The patients did not fulfill all the 
required ARDS criteria at the time of inclusion [2]. Those who 
fulfilled ARDS criteria within one week of the stay in ICU were 
randomized to an ARDS group, the others to a non-ARDS group.  
 
We divided those who fulfilled the clinical, radiological and 
cardiologic criteria of ARDS into mild - , moderate – or severe 
ARDS with the characteristics listed below. Mild ARDS: 200 
mmHg < PaO2/FiO2 ≤ 300 mmHg, CPAP or PEEP ≥ 5 cm H2O; 
moderate ARDS: 100 mmHg < PaO2/FiO2 ≤ 200 mmHg, PEEP ≥ 
5 cm H2O and severe ARDS: PaO2/FiO2 ≤ 100 mmHg, PEEP ≥ 5 
cm H2O, according to the definition [2]. 
 
Exclusion Criteria  
 
We excluded patients below 18 years of age, patients receiving 
mechanical ventilation with no ARDS predisposing condition, 
patients not fulfilling the study protocol, and patients from whom 
we did not get consent for participation. We also excluded 
patients after transthoracic echocardiography (ECHO) displaying 
ejection fraction (EF) <50% and right ventricular systolic 
Prime Archives in Medicine: 2
nd
 Edition 
7                                                                                www.videleaf.com 
pressure > 35 – 40 mm Hg, and with a pulmonary artery 
occlusion pressure > 18 mm Hg, as measured if a Swan Ganz 
catheter was in place.   
 
Study Protocol  
 
We determined plasma concentrations of TF, t-PA and PAI-1 at 
enrollment (T0) and on the third day (T3) and the seventh day 
(T7) of the ICU stay. Moreover, we noticed ventilator settings 
including FiO2, tidal volume, airway plateau pressure and PEEP-
levels that were titrated by means of the trans-pulmonary 
pressure-volume curve displayed on the Servo-I ventilator, and 
the resulting readings of PaO2/FiO2 and lung mechanical 
parameters from every subject at the time of collection of plasma 
samples. We also recorded number of days on mechanical 
ventilation, ventilator-free days at day 30 of the stay in ICU and 
the 30-day mortality rate. 
 
We observed the patients in ICU for one week and compared 
plasma concentrations of coagulation and fibrinolysis biomarkers 
between those who developed ARDS and those who did not 
develop the disease (non-ARDS), as based on recent criteria [2]. 
Demographic and clinical data and direct and indirect ARDS risk 
factors were retrieved from the medical records of the patients. 
The severity of disease was scored at inclusion using the 
Sequential Organ Failure Assessment (SOFA) and the Acute 
Physiology and Chronic Health Evaluation (APACHE II) scores. 
In addition, we calculated Lung Injury Prediction Score (LIPS) 
for every patient at the day of inclusion (T0). 
 
Determination of Biomarkers of Coagulation and 
Fibrinolysis  
 
We collected blood from a peripheral vein into heparin tubes that 
we cool centrifuged (ELMI CM-6MT®, USA) for 5 minutes at 
3,000 x g. The plasma supernatant was removed from the spun 
samples and frozen at -70 °C until the time of analysis. Human 
tissue factor (TF)(CD264) with a normal range of from 12.5 
pg/ml to 400 pg/ml, was quantitatively assessed by means of an 
enzyme-linked immunosorbent assay (ELISA) test (Abcam
®
, 
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UK). Fibrinolysis markers, t-PA (normal range 15.6 – 1.000 
pg/ml) and PAI-1 (normal range 78 – 5.000 pg/ml) were 
analyzed with the same method using the platinum ELISA kit 
(eBioscience
®
, USA).  
 
In parallel, we analyzed standard coagulation tests (SCT) such as 
prothrombin index (PI), International Normalized Ratio (INR) 
and fibrinogen plasma concentration, as well as platelet count 
(PLT), which was analyzed by means of a Beckman Coulter LH 
750 Hematology Analyzer (Beckman Coulter International SA, 
Switzerland). Coulter LH 750 uses impedance technology to 
measure PLT count (normal range 150 - 450 x 10
9
/L). 
Fibrinogen plasma concentration was analyzed in citrated plasma 
(Multifibren U reagent, Siemens Healthcare Diagnostics, 
U.S.A.). The reference value is 1.8 - 3.6 g/L. PI was analyzed 





 reagent, Siemens Healthcare Diagnostics, U.S.A.). PI 
normal range is 70 - 120%. APTT was analyzed in citrated 
human plasma (Pathrombin*SL reagent, Siemens Healthcare 
Diagnostics, U.S.A.). APTT normal range is 26 - 36 s. 
 
Statistical Analysis and Sample Size Calculations  
 
Statistical analyses was performed using SPSS Statistics 
(Chicago, IL, Version 20). We compared ARDS patients and 
non-ARDS patients and survivors and non-survivors of the 
disease. Data distribution was assessed using Shapiro-Wilk test 
or Kolmogorov Smirnov test, as appropriate. We used 
descriptive statistics for analysis of baseline demographics and 
clinical data, and Chi-square or Mann-Whitney Rank sum test to 
compare the difference between groups. If the F value was 
greater than critical, repeated measures ANOVA was followed 
by Holm-Sidak’s post hoc test for pairwise multiple comparisons 
to check for intragroup differences. For non-normally distributed 
data, the results were presented as boxes with median and 
interquartile range (IQR; 25–75 percentile) including vertical 
error bars for the 10% and 90% lowest and highest values, 
respectively. Correlations were presented as Spearman’s rs [26]. 
We performed receiver operating characteristic (ROC) curve 
analysis of coagulation - and fibrinolytic biomarkers including 
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calculations of area under the curve (AUC) for TF and PAI-1 to 
demonstrate their efficiency in supporting ARDS diagnosis. 
Spearman’s correlation coefficient also was calculated to analyze 
the relationships between coagulation/fibrinolysis markers and 
ventilation parameters. Statistical significance was defined as p < 
0.05. When required, we calculated sample sizes needed to reach 
significant differences (p < 0.05) in plasma concentrations of TF, 
PAI-1 and t-PA at a power of 80% between the ARDS group and 





As depicted in Figure 1, we assessed 33 mechanically ventilated 
patients, considered to be at risk of developing ARDS, for 
suitability to the study. We excluded seven patients who died 
before they fulfilled all the requirements of the study protocol, 
and two patients from whom we did not get consent for 
participation.  
 
Table 1 displays demographic characteristics and clinical 
variables of 24 patients (21 men and 3 women) fulfilling 
inclusion criteria and all requirements of the protocol 
encompassing comorbidities, conditions predisposing for ARDS, 
severity scores and standard coagulation variables. Pneumonia 
(46%) was the most common underlying disease. However, 
neither ARDS nor non-ARDS patients displayed significant 
intergroup differences with regard to demographic data, 
comorbidities or predisposing conditions. Patients diagnosed 
with ARDS had significantly higher baseline values of SOFA, 
APACHE II and LIPS scores. Moreover, the ARDS group 
showed significant differences in systemic coagulation (elevated 
INR, lower PLT and fibrinogen plasma levels), but no clinical 
signs of DIC. The mean time for developing ARDS was 3 ± 2 
days after inclusion. Six patients developed mild ARDS, whereas 
moderate or severe ARDS occurred within one week of the 
inclusion in four patients each, thus constituting in all 58% of the 
population at risk. Days in ICU and ventilator-free days at Day 
30 displayed no intergroup differences. Total hospital mortality 
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and mortality at Day 30, reached 25%, but displayed no 




Figure 1: Mechanically ventilated patients considered for eligibility to a 
prospective pilot study. 
Twenty-four patients fulfilled the study protocol. SCT, standard coagulation 
tests; APACHE II, Acute Physiology and Chronic Health Evaluation II; SOFA, 
Sequential Organ Failure Assessment; LIPS, Lung Injury Prediction Score. 
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Table 1: Baseline Demographic Characteristics, ARDS Predisposing Factors and Mortality. 
  







Age, years 54 ± 17 55 ± 15 53 ± 19 0.7 
Women, n (%) 3 (12) 2 (14) 1 (10) 0.8 
BMI 
 
26.4 ± 4.6 
 
24.7 ± 2.8 
 




Comorbidities     
Hypertension, n (%) 
Diabetes mellitus, n (%) 













Conditions predisposing for ARDS     
Pneumonia, n (%) 11 (46) 6 (42) 5 (50) 0.7 
Sepsis, n (%) 7 (29) 4 (29) 3 (30) 0.9 
Pancreatitis, n (%) 5 (21) 4 (29) 1(10) 0.3 
Massive transfusions, n (%) 1 (4) 0 1 (10) 0.2 
Severity scores     
SOFA, median (range) 4 (3.4- 6.1) 5 (4.6- 7.2) 3 (2.1- 4.9) 0.04 
APACHE II, median (range) 
LIPS median (range) 
23 (19- 28) 

















PLT (109/L)                            
Fibrinogen (mg/dl) 
ICU stay and mechanical ventilation 
1.18 ± 0.4 
172 ± 56 
283 ± 71 
 
 
1.2 ± 0.6 
136 ± 47 
261 ± 96 
 
 
1.12 ± 0.15 
213 ± 31 








ICU days, n 12 ± 5 14 ± 7 11 ± 4 0.7 
Ventilator- free days, n 5 ± 3 4 ± 2 7 ± 4 0.4 
Mortality     
Hospital, n (%) 6 (25) 4 (29) 2 (20) 0.1 
30-day, n (%) 6 (25) 4 (29) 2 (20) 0.1 
 
Data are presented as mean ± SD, number (n) or median (range) 
APACHE II, Chronic Health Evaluation score; ARDS, acute respiratory distress syndrome; BMI, Body mass index; ICU, Intensive care unit; INR, International Normalized Ratio; LIPS, Lung Injury 
Prediction Score; n, number of patients; PLT, platelets; %, percent; range, lowest and highest value; SOFA, Sequential Organ Failure Assessment score 
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Table 2 displays ventilation parameters and PaO2/FiO2 at T0, T3 
and T7. Tidal volumes were significantly smaller at T0 and T7 in 
ARDS patients, as compared to the Non-ARDS group. Despite 
that plateau pressures were significantly higher in the ARDS 
group at T3 and T7, and PEEP also was significantly raised at the 
latter time point, these ventilator settings did not prevent a 
significant fall in PaO2/FiO2 in comparison with the non-ARDS 
group. 
 
Table 2:  Ventilation Variables at Inclusion (T0) and at the Third (T3) and 






















6.7 – 8.9 






8.8 – 11.3 
8.9 – 10.1 


















22 – 35 
23 – 36 








21 – 27 
22 – 30 















42 – 282 
94 – 362 






74 – 348 
58 – 358 















5 – 11 
5 – 13 






3 – 7 
4 – 7 






Data are presented as Median and Interquartile range (IQR) 
ARDS, acute respiratory distress syndrome; cmH20, centimeters of water; 
FiO2, Fraction of inspired oxygen; kg, kilograms; ml, milliliters; N, number of 
patients; PaO2, Partial pressure of oxygen in blood; PEEP, positive end-
expiratory pressure; NS, not significant. 
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Comparison of Coagulation and Fibrinolysis in ARDS 
vs. Non-ARDS Patients  
 
Plasma concentrations of TF (Figure 2A) remained within 
normal range with no significant difference between ARDS and 
non-ARDS group at T0 (p = 0.229), but displayed marked 
intergroup differences at T3 (p = 0.043) and T7 (p=0.022). The 
ARDS group also showed intragroup differences in TF plasma 
concentrations between the highest value at T7 in comparison 
with those at T0 and T3, respectively (p < 0.001). In contrast, we 
found no significant intragroup differences in the plasma levels 
of TF in the non-ARDS group.  
 
Plasma levels of PAI-1 (Figure 2B) showed no intergroup 
differences at T0 and T3, but increased at T7 in the ARDS group, 
as compared with Non-ARDS group (p = 0.026). Plasma 
concentration of PAI-1 at T7 in the ARDS group was also 
increased in comparison with intragroup values at T0 (p = 0.016) 
and T3 (p = 0.017), but not no significant difference was found 
between the latter concentrations. Plasma levels of t-PA fell at T3 
(Figure 2C), but we noticed no significant differences within or 
between the groups. At T3, plasma concentration of t-PA was 295 
± 85 (mean ± SD) pg/ml in ARDS survivors vs. 516 ± 160 pg/ml 
in ARDS non-survivors, but the difference did not reach 
significance due to low sample size.   
 
We found significant correlations between plasma concentrations 
of TF and PAI-1 (r = 0.53; p = 0.008), TF and PaO2/FiO2 (r = - 
0.65; p = 0.001) and PEEP and TF (r = 0.55; p = 0.005) at time 
T7, as depicted in Figures 3A, 3B and 3C. 
 
In ARDS patients, a ROC analysis (Figure 4) showed 71 % 
sensitivity and 100 % specificity for an association with TF at T7 
with a cut off value of 145 pg/ml (AUC 0.782; p = 0.021;95% 
confidence interval (95%CI):  0.586 - 0.979. We also found an 
association with PAI-1 determined at the same time point with a 
sensitivity and specificity of 64% and 100%, respectively, with a 
cut off value of 117.5 pg/ml (AUC 0.775; p = 0.024, 95%CI:  
0.584 - 0.966.  
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Figure 2: Plasma Concentrations of Markers of Coagulation and Fibrinolysis in 
ARDS and non-ARDS Patients. 
A  Plasma concentration of Tissue factor (TF) vs. time in an ARDS group and a 
non-ARDS group. Data presented as median and interquartile range with 10th 
and 90th percentiles error bars. T0 is day of enrollment, T3 and T7, the third day 
and the seventh day of ICU stay.  *denotes intergroup p = 0,043 at T3 and 
p=0.022 at T7, respectively. # denotes ARDS intragroup p=<0.001 between T7 
and T0 and T3, respectively. pg/ml, picogram per milliliter; closed circles 
represent outliers. 
B Plasma concentrations of Plasminogen activator inhibitor-1 (PAI-1) vs. time 
in an ARDS group and a non-ARDS group. Data presented as median and 
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interquartile range with 10th and 90th percentiles error bars. T0 is day of 
enrollment, T3 and T7, the third day and the seventh day of ICU stay. *denotes 
intergroup p=0.026 at T7. # denotes ARDS intragroup p=0.016 between T7 and 
T0 and P=0.017 between T7 and T3. pg/ml, picogram per milliliter; closed 
circles represent outliers. 
C  Plasma concentration of tissue plasminogen activator (t-PA) vs. time in an 
ARDS group and a non-ARDS group. Data presented as median and 
interquartile range with 10th and 90th percentiles error bars. T0 is day of 
enrollment, T3 and T7, the third day and the seventh day of ICU stay. No 





In this prospective pilot study, 14 out of totally 24 patients 
considered to be at increased risk of ARDS, developed the 
disease within seven days of commencement of mechanical 
ventilation. Patients diagnosed with ARDS had significantly 
higher baseline severity scores in comparison with the non-
ARDS group, which could indicate a worse outcome. However, 
mortality did not differ significantly between groups (Table 1). 
In the ARDS group, PaO2/FiO2 reached nadir on the seventh day 
of the ICU stay, in parallel with significant changes in variables 
of coagulation and fibrinolysis. In patients diagnosed with 
ARDS, plasma concentrations of TF and PAI-1 increased 
significantly at T7, as compared with the non-ARDS group. The 
observation of increased TF is consistent with recent findings in 
patients with sepsis-induced ARDS [5]. Therefore, our findings 
suggest a role for these biomarkers as supportive diagnostic tools 
during the emergence of ARDS.  
 
Development of ARDS in a population at risk depends on both 
genetic predisposition and interaction between several biological 
pathways, including inflammation, coagulation and fibrinolysis 
[20]. We intentionally observed patients in the ICU for one week 
after inclusion for biomarker detection. This was inspired by 
observational studies suggesting that the majority of patients are 
identified with ARDS within 72 h of the recognition of risk 
factors, and nearly all within 7 days of hospital stay [23,26,27]. 
However, in spite of our efforts to keep low tidal volumes and to 
titrate PEEP to a point above the lower inflection of the trans-
pulmonary pressure-volume curve, yielding optimal 
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oxygenation, both tidal volume and plateau pressure increased 
significantly at T7, and we were not able to prevent PaO2/FiO2 
from falling in the ARDS group. This is consistent with the 
derangements in oxygenation and lung mechanics in developing 
ARDS, as reported by other researchers [2,15].  
 
ARDS and Biomarkers of Coagulation and Fibrinolysis  
 
Investigators have focused on different biomarkers of ARDS 
[3,5,20,25], but so far, without significant preferences. Protein C 
plasma levels are reduced in patients with severe sepsis [27] and 
in victims of ARDS, due to a greater consumption of this 
anticoagulant and anti-inflammatory protein [20,21]. However, 
when it was discovered that replacement therapy with 
recombinant human activated protein C had no significant effect 
on survival, neither from severe sepsis nor from ARDS, the 
interest in protein C vanished [28,29]. Alterations in plasma 
coagulation and fibrinolysis have not yet been evaluated in view 
of the latest diagnostic criteria of ARDS that define ‘‘acute 
onset’’ as a condition developing within one week of a known 
insult, or a new  or worsening respiratory failure [30].  
 
We included patients during a one-year period since some of the 
conditions with increased risk of ARDS, like influenza and 
pneumonia have their seasonal peaks. To detect a possible 
significance of plasma concentrations of TF, PAI-1 and t-PA, as 
diagnostic markers, we studied an ICU population, which had 
increased risk of ARDS and required mechanical ventilation for 
at least 24 hours. Several researchers have suggested a potential 
association between TF and the occurrence of ARDS. TF 
appears to play a pivotal role both in regulating endothelial 
permeability and in activating the external coagulation pathway 
in severe infections [5,31,32]. Moreover, investigators 
demonstrated higher plasma TF levels in parallel with lower 
platelet counts and higher incidence of DIC in patients with 
ARDS, in whom the primary injury was trauma or sepsis [31]. 
Recently, Xue and co-workers found that, patients with sepsis-
induced ARDS had significantly higher levels of TF on the day 
of admission as compared with non-ARDS patients. The AUC 
for the diagnosis sepsis- induced ARDS was 0.749. These 
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investigators concluded that TF is an independent predictor of 
30-day mortality in patients with severe sepsis (OR 1.41; 95% CI 
1.24-1.69) with AUC 0.718 [5]. Consistent with the latter 
workers, we showed that TF increased significantly the seventh 
day after inclusion in the ARDS group as compared with non-
ARDS patients (Figure 2A). A ROC curve analysis displayed a 
sensitivity of 71% with AUC of 0.78, p=0.02, which indicates a 
fair test value in favor of diagnosing ARDS, according to the 
published criteria [2,5]. However, we did not observe any 
correlation between TF and DIC, since none of our patients was 
diagnosed with that condition. In contrast, TF plasma levels 
correlated moderately with ventilation parameters (Figures 3B 
and 3 C), most likely, because of a high proportion of patients 
with pneumonia (42%) in the ARDS group. Therefore, we 
consider TF to be a tool for supporting ARDS diagnosis, but 
without any predictive value since the increase in plasma 
concentration occurred after one week of ICU stay.  
 
In the present study, PAI-1 plasma concentration also increased 
significantly in ARDS patients on the seventh day of stay in ICU 
(Figure 2B). The rise in PAI-1 correlated slightly with a parallel 
increase in TF (Figure 3A) and ROC curve analysis (Figure 4) 
revealed a sensitivity of 64% with AUC of 0.775; p=0.024, 
which indicates a somewhat poorer test in favor of diagnosing 
ARDS, as compared with the corresponding test of TF. Previous 
investigators have noticed that ARDS patients exhibit early 
elevation of PAI-1 activity in both plasma and air spaces in 
concert with a decrease in alveolar fibrinolysis [33,34]. Thus, El 
Solh and co-workers showed that tracheal aspirate PAI-1 antigen 
levels, sampled eight hours after witnessed aspiration, increased 
by a fivefold in those who progressed to ARDS, as compared 
with those with uncomplicated aspiration pneumonitis [35]. The 
reason for the discrepancy between our results and those of the 
latter researchers, aside from different analytic techniques, could 
be that changes in tracheal aspirate PAI-1 antigen concentration 
occurs earlier as compared to the changes in plasma 
concentration [33]. 
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Figure 3: Correlations between Tissue Factor (TF) and Plasminogen activator 
inhibitor-1 (AI-1) and Ventilation Parameters on the Seventh Day (T7) of ICU 
Stay. 
A Relationship between plasma concentrations of TF and PAI-1 in 24 ICU 
patients. Data presented as Spearman’s correlation coefficient (r) with p - 
value. TF, Tissue factor; PAI-1, plasminogen activator inhibitor; pg/ml, 
picogram per milliliter.   
B Relationship between plasma concentrations of TF and PaO2/FiO2 in 24 ICU 
patients. Data presented as Spearman’s correlation coefficient (r) with p-value. 
PaO2, arterial oxygen partial pressure. FiO2, fraction of inspired oxygen. TF, 
Tissue factor; pg/ml, picogram per milliliter.  
C Relationship between plasma concentrations of TF and level of PEEP in 24 
ICU patients. Data presented as Spearman’s correlation coefficient with P 
value. PEEP, positive end-expiratory pressure; cmH2O, centimeter of water; 
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Figure 4: ROC Curves Showing Sensitivity and Specificity of Tissue Factor 
and Plasminogen Activator Inhibitor-1 for ARDS Diagnoses on the Seventh 
Day (T7) of ICU Stay. 
ARDS group displaying 71 % sensitivity and 100 % specificity for association 
with plasma concentration of TF. Cut off value: 145 pg/ml; AUC 0.782; 
p=0.021; 95%CI: 0,586 - 0,979. Correspondingly, plasma concentration of PAI-1 
showed sensitivity and specificity of 64% and 100%, respectively, and a cut off 
value of 117.5 pg/ml; AUC 0.775; p=0.024; 95%CI:  0,584 - 0,966. AUC, area 
under the curve; 95%CI, 95% confidence interval; PAI-1, plasminogen activator 
inhibitor-1; ROC, receiver operating characteristics; TF, tissue factor. 
 
Lately, Sapru and co-workers demonstrated in pediatric patients, 
that increased plasma concentrations of PAI-1, as determined the 
day after diagnosing ARDS, were associated with increased 
mortality and fewer ventilator free days until Day 28 [25]. 
Furthermore, investigators who showed that plasma 
concentrations of PAI-1 increased from Day 0 to Day 3 after 
diagnosing ARDS, predicted death with an odds ratio of 1.66 (P 
= 0.006) [21]. Moreover, a prospective study of 50 patients with 
ARDS at an early stage, showed significantly higher PAI-1 
levels in those who died as compared with those who survived 
[20]. However, we confirmed none of the latter findings in this 
pilot study, which was underpowered for such investigations. 
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As an acute-phase protein, the serine protease inhibitor PAI-1 
binds covalently to t-PA, reduces formation of plasmin and 
impedes fibrinolytic bleeding. Moreover, recent experimental 
studies indicate that PAI-1 also plays a role in upregulating 
inflammation after exposure to lipopolysaccharides or avian flu 
virus in conditions like ARDS [36,37]. However, in the present 
study, when we compared the ARDS group with non-ARDS 
patients, we found no significant differences in t-PA levels 
during the first week after inclusion. Thus, whether t-PA is a 
predictive marker of ARDS is still not concluded, but this 
hypothesis was not supported in the present prospective pilot 
study.  
 
We admit that our study has several limitations because of the 
small number of patients included. For that reason, we could not 
expect to find significant differences between groups neither in 
ICU stay and mechanical ventilation, nor in mortality rates. 
Despite the fact that we found a lower plasma concentration of t-
PA at T3 in ARDS survivors in comparison with non-survivors, 
the test had a power of only 60 % due to low sample size. 
However, by keeping the ratio between the groups unchanged, 
an increase in sample size to 14 survivors and 6 non-survivors, 
would give a significant difference with a power of 80%. 
Correspondingly, to reach a significant intergroup difference in 
t-PAI with the same power at T7, would require a total sample 
size of 317 patients. Therefore, due to low sample sizes, we were 
not able to strengthen our findings by means of multivariate 
analysis. Since mean time to diagnosing ARDS was on the 
average three days, we also admit as a limitation of any 
predictive role, the fact that most of the patients already had 
ARDS at the time of plasma sampling at T3, whereas significant 
changes in TF and PAI-1 occurred first at T7. Nevertheless, our 
observations indicate a role for TF and PAI-1 as tools for 
supporting ARDS diagnosis, although significant changes 
occurred relatively late in the evolution of disease. 
 
We also denote as a weakness of this study that the ARDS 
patients incorporated many serious risk factors and comorbidities 
when admitted to the ICU. Therefore, those who were included 
had different lengths of hospital stays before admission to the 
Prime Archives in Medicine: 2
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ICU. However, the prior history was not an issue for evaluation 
in the present study. 
 
According to ARDS definition [2], we should be able to identify 
patients with mild ARDS that potentially correlates with a better 
prognosis. However, besides a low number of patients included, 
we did not follow oxygenation variables often enough to be able 
to evaluate them properly against changes in ventilator settings, 
or other variables on an hourly basis. For the same reason, 
changes in concentrations of biomarkers that might have taken 
place, between the days of plasma sampling remain 
undiscovered. We also realize that sampling of broncho-alveolar 
lavage fluid, in parallel with the plasma samples, could have 
strengthened the findings, and maybe enabled the discovery of 
changes in biomarkers at an earlier time point. 
 
A limitation is also the course of ARDS development that may 
influence the changes in biomarkers and outcome significantly. 
We included only patients with high risk of developing ARDS, 
but even among them, particularly patients with severe 
pneumonia have a poor prognosis in comparison with victims of 
multi-trauma and/or those undergoing massive blood 
transfusions. Finally, due to limited sample sizes, the findings of 
this pilot study need confirmation in a larger randomized 




Fourteen of 24 patients on mechanical ventilation whom we 
suspected to be at increased risk, developed ARDS on the 
average 3 days after admission to the ICU. Activation of the 
coagulation and the fibrinolytic systems in terms of increased 
plasma levels of TF and PAI-1 occurred on the seventh day of 
ICU stay in patients diagnosed with ARDS, thus indicating a 
supportive diagnostic role for these biomarkers. Our findings 
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